Total Raised
$43.1MInvestors Count
19Deal Terms
2Funding, Valuation & Revenue
8 Fundings
Coulter Pharmaceutical's latest funding round was a Acq - P2P for on December 20, 2000.
Coulter Pharmaceutical's valuation in January 1997 was $120.12M.
Coulter Pharmaceutical's latest post-money valuation is from December 2000.
Sign up for a free trial to see Coulter Pharmaceutical's valuations in December 2000 and more.
Date | Round | Amount | Investors | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Revenue | Sources |
---|---|---|---|---|---|---|
12/20/2000 | Acq - P2P | 1 | ||||
8/14/2000 | PIPE | |||||
1/28/1997 | IPO | $120.12M | ||||
1/1/1997 | Unattributed - II | |||||
4/1/1996 | Unattributed |
Date | 12/20/2000 | 8/14/2000 | 1/28/1997 | 1/1/1997 | 4/1/1996 |
---|---|---|---|---|---|
Round | Acq - P2P | PIPE | IPO | Unattributed - II | Unattributed |
Amount | |||||
Investors | |||||
Valuation | $120.12M | ||||
Revenue | |||||
Sources | 1 |
This profile has not been claimed.
You're more than your latest funding, tell our customers your company's story.
Coulter Pharmaceutical Deal Terms
2 Deal Terms
Coulter Pharmaceutical's deal structure is available for 2 funding rounds, including their Acq - P2P from December 20, 2000.
Round | Acq - P2P | IPO |
---|---|---|
Funding Date | ||
Pre-Money Valuation | ||
Post-Money Valuation | ||
Amount Raised | ||
Shares Authorized | ||
Issuance Price | ||
Dividend Rate | ||
Liquidation Preferences | ||
Liquidation Price | ||
Participation | ||
Conversion Price | ||
Anti Dilution | ||
General Voting | ||
Board Voting | ||
Par Value |
Round | Funding Date | Pre-Money Valuation | Post-Money Valuation | Amount Raised | Shares Authorized | Issuance Price | Dividend Rate | Liquidation Preferences | Liquidation Price | Participation | Conversion Price | Anti Dilution | General Voting | Board Voting | Par Value |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Acq - P2P | |||||||||||||||
IPO |
Coulter Pharmaceutical Investors
19 Investors
Coulter Pharmaceutical has 19 investors. Corixa invested in Coulter Pharmaceutical's Acq - P2P funding round.
First funding | Last Funding | Investor | Rounds | Board Seats | Type | Location |
---|---|---|---|---|---|---|
12/20/2000 | 12/20/2000 | 1 Acq - P2P | Corporation | Washington | ||
8/14/2000 | 8/14/2000 | 1 PIPE | Corporation | Massachusetts | ||
8/14/2000 | 8/14/2000 | 1 PIPE | ||||
Asset/Investment Management | Connecticut | |||||
Diversified Financial Services | New York |
First funding | 12/20/2000 | 8/14/2000 | 8/14/2000 | ||
---|---|---|---|---|---|
Last Funding | 12/20/2000 | 8/14/2000 | 8/14/2000 | ||
Investor | |||||
Rounds | 1 Acq - P2P | 1 PIPE | 1 PIPE | ||
Board Seats | |||||
Type | Corporation | Corporation | Asset/Investment Management | Diversified Financial Services | |
Location | Washington | Massachusetts | Connecticut | New York |
Compare Coulter Pharmaceutical to Competitors
Ligon Discovery is a drug discovery company built around the firm's primary technology platform, Small-Molecule Microarrays (SMMs).
Brain Tunnelgenix Technologies provides medical devices and equipment services. It offers non-invasive and continuous wearable technology that tracks human brain temperature through the brain's thermal tunnel. Brain Tunnelgenix Technologies was founded in 2006 and is based in Aventura, Florida.
Mercator MedSystems has developed a broad-based therapeutic platform that allows clinicians to accurately and efficiently deliver drugs and biologics such as stem cells to tissues deep in the body, treating the root cause of significant medical conditions. The company utilizes its family of Micro-Infusion Catheters for targeted treatments via the vascular system, including peripheral artery disease (PAD) and resistant hypertension (HTN); and via the bronchial tree, including malignant airway obstruction secondary to lung cancer. The company's 510(k)-cleared and CE-Marked Cricket and Bullfrog Micro-Infusion Catheters are vascular-access systems that are able to inject drugs, genes, and cells safely through vessel walls into deep tissues without major surgery.
Rafael Medical has developed a novel anchoring system for safely implanting and retrieving a wide range of intra-vascular devices in a minimally invasive manner. Based on the technology, diagnostic and therapeutic devices can be delivered into small and large blood vessels alike by way of a small-sized delivery system. Following the completion of the SafeFlo Filter the company is now developing additional devices geared to the interventional cardiology market.
Lifepoint is a medical technology company developing rapid and cost effective, non-invasive, on-site diagnostic products. The Company has developed and will continue to develop patented, proprietary technologies utilizing saliva as a test specimen to provide blood equivalent diagnostic results without the need for blood or urine.
TrueVision Systems, dba TrueVisions 3D Surgical, provides digital 3D visualization and guidance for microsurgery. The company has developed an intelligent, real-time, 3D surgical visualization and computer-aided guidance platform. TrueVision combines 3D visualization and guidance software applications focused on improving accuracy, efficiency, and outcomes for both surgeons and patients. The company is developing 3D guidance applications for microsurgery to improve surgical efficiencies and patient outcomes. The Refractive Cataract Toolset is a computer-aided software for astigmatic correction and advanced IOL positioning.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.